Prisum Healthcare becomes a member of the PPTA (Plasma Protein Therapeutics Association), the leading global association in the human blood plasma-derived products industry. July 2025

Prisum Healthcare has officially joined the Plasma Protein Therapeutics Association (PPTA) as an associate member. The PPTA is the foremost global organisation representing the unique sector of biological and biotechnology industries. The association represents over one thousand plasma collection centres across the United States and Europe, as well as the leading manufacturers of human blood plasma-derived therapies.

Prisum Healthcare’s recognition as an associate member of the PPTA follows a rigorous selection and validation process, during which the company demonstrated operational excellence, a sustainable regional growth strategy, and a genuine commitment to ethics, responsibility, and equitable access to life-saving treatments.

Through this affiliation, Prisum Healthcare becomes part of a global network dedicated to upholding the highest standards of quality and safety in the collection, processing, and use of human plasma. The company will play an active role in raising awareness about the importance of blood plasma donation and participating in both national and international regulatory initiatives in line with current legislation.

A Long-Term Commitment to Accessing Life-Saving Therapies

In the letter confirming Prisum Healthcare’s associate member status, the PPTA stated:

“Achieving membership is a recognition of [Prisum Healthcare’s] long-term efforts in maintaining a distribution activity founded on ethical principles and operational excellence. Prisum Healthcare’s dedication to improving patient access to human plasma-derived therapies reflects the values guiding our work in the global plasma community.”

“Joining the PPTA affirms the direction in which we are evolving: from Romania’s leading immunoglobulin supplier, we are becoming an active and trusted partner in building a healthy, ethical, and strictly regulated ecosystem for plasma-based therapies. We embrace this responsibility to help ensure easier access for patients to life-saving treatments. Membership in an association like the PPTA both honours us and obliges us. Our top priority has always been, and remains, patient well-being, and our investments in this direction speak for themselves,” said Ionela Nicolau, CEO of Prisum Healthcare.

From Distribution to Strategic Investments in Plasma Collection

Recently, Prisum Healthcare has strengthened its position in the human blood plasma-based therapies sector, developing strong partnerships with global leaders and planning to expand its operations through the acquisition of plasma collection centres in Germany. The company also aims to establish a regional network of such centres in Romania, Greece, and other countries where Prisum Healthcare operates, as soon as legislation allows.

“Recognition as an associate member of the PPTA comes at a pivotal moment for our company. We plan to invest in the vertical development of Prisum Healthcare, specifically in human plasma collection and geographic expansion, thereby contributing to easier patient access to essential therapies. We want to support the development of plasma collection capacity directly and to help ensure that patients in Romania, Greece, and other countries in the region can access essential therapies under equitable and safe conditions,” said Sumer Tyagi, Development Director at Prisum Healthcare.

A New and Strong Voice in the Global Plasma Therapies Community

Membership in the PPTA provides Prisum Healthcare not only with greater visibility but also with a solid framework for collaboration and legitimacy in shaping the future of human plasma-based therapies. From promoting essential therapies to engaging in institutional dialogue and contributing to the alignment of national regulations with European and international standards, Prisum Healthcare aims to be a constructive and consistent partner in this critical healthcare sector.

“Our company’s affiliation with the Plasma Protein Therapeutics Association strengthens our voice and role within the global community of human plasma industry stakeholders. At the same time, it gives us the opportunity to actively participate in the positive transformation of this sector, to the benefit of patients who depend on complex, life-saving therapies,” concluded Ionela Nicolau, CEO of Prisum Healthcare.

* * *

Prisum Healthcare is one of the most important companies in Romania’s dietary supplements market and a key supplier of human plasma-derived products that save lives.